Description
AMJEVITA (adalimumab-atto) is a biosimilar medication to Humira, containing the active ingredient adalimumab, a monoclonal antibody that blocks tumor necrosis factor (TNF) to reduce inflammation. It's administered via subcutaneous injection in strengths like 20 mg/0.4 mL and 40 mg/0.8 mL, used to treat autoimmune conditions such as rheumatoid arthritis, psoriasis, and inflammatory bowel disease. Manufactured by Amgen Inc., it's a prescription drug approved under BLA761024. This information was generated using AI and is provided for informational and research purposes only.
Resources
| Name | Format | Description | Link |
|---|---|---|---|
| Adalimumab-atto | HTML | Access the FDA dataset for Adalimumab-atto — ANDA 761024 submitted by Mylan Institutional LLC | Open resource |